Oncotarget

Research Papers:

HER2 reduces breast cancer radiosensitivity by activating focal adhesion kinase in vitro and in vivo

Jing Hou, Zhirui Zhou, Xingxing Chen, Ruping Zhao, Zhaozhi Yang, Na Wei, Qing Ni, Yan Feng, Xiaoli Yu, Jinli Ma and Xiaomao Guo _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2016; 7:45186-45198. https://doi.org/10.18632/oncotarget.9870

Metrics: PDF 1653 views  |   HTML 2480 views  |   ?  


Abstract

Jing Hou1,*, Zhirui Zhou2,3,*, Xingxing Chen2,3,*, Ruping Zhao4, Zhaozhi Yang2,3, Na Wei1, Qing Ni1, Yan Feng2,3, Xiaoli Yu2,3, Jinli Ma2,3, Xiaomao Guo2,3

1Department of Breast surgery, Guizhou Provincial People's Hospital, Guiyang 550002, Guizhou Province, China

2Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai 200032, China

3Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China

4Department of Radiation Oncology, Hangzhou Cancer Hospital, Hangzhou 310006, Zhejiang, China

*These authors contributed equally to this work

Correspondence to:

Xiaomao Guo, email: guoxm1800@163.com

Jinli Ma, email: jinlima_c@yahoo.com

Keywords: breast cancer, radiosensitivity, HER2, focal adhesion kinase, anoikis

Received: March 06, 2016     Accepted: May 17, 2016     Published: June 07, 2016

ABSTRACT

Growing evidence has demonstrated that human epidermal growth factor receptor 2 (HER2) is involved in the radiation response to breast cancer. However, the underlying mechanism remains elusive. Therefore, we investigated if HER2 overexpression is associated with radiosensitivity of breast cancer. We constructed breast cancer cell lines differing in HER2 expression by transducing HER2 cDNA or short hairpin RNA against HER2. We then assessed the radiosensitivity and investigated the potential mechanism by using cell proliferation assay, cell adhesion assays, anoikis assays, colony formation assays, and western blotting analyses. We found that HER2 introduction in breast cancer cell lines MCF-7 (low HER2 expression) and MDA-MB-231 (HER2 is not expressed) promoted cell proliferation and invasion and enhanced cell adhesion and resistance to anoikis. Moreover, HER2 reduced radiosensitivity in these two cells compared with the corresponding control. The opposite results were observed when HER2 was silenced in breast cancer cell lines ZR-7530 and SK-BR-3 (both cells with high expression of HER2) using HER2 shRNA. In addition, animal experiment results showed HER2 could enhance the radioresistance of xenograft tumors. Further studies showed HER2 promoted the phosphorylation of focal adhesion kinase (Fak) and thereby up-regulated the expression of proteins associated with the epithelial-to-mesenchymal transition such as Claudin-1, ZO-1, and ZEB-1. The inhibition of Fak activity using the Fak inhibitor (PF-562281) restored the radiosensitivity in HER2-overexpressing cells. In conclusion, HER2 reduces the radiosensitivity of breast cancer by activating Fak in vitro and in vivo. Fak might be a potential target for the radiosensitization of HER2-overexpressed breast cancer.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 9870